Kornimate/medical-research-clean huggingface dataset:
development of a couple-based mindfulness intervention for chronic pain

Conditions: Chronic Pain

Summary: chronic pain is a costly public health problem that is associated with poor quality of life. previous research has demonstrated extensive evidence showing that pain coping is not manifested by patients in isolation but within the context of significant relationships such as marriage. for instance, a partner may avoid or reject their partners' negative emotions about pain, provide unempathic responses to their partners' pain, or change their thoughts about pain. the patient's pain experience and the couples' relationship also have a cyclical relationship, in which both can affect each other and the overall quality of life for both partners. currently, current clinical practice does not target both partners to alleviate pain. this is highly problematic given that a number of chronic pain patients-those with interpersonal distress-often do not complete, and thus, do not benefit fully from existing treatments. even if treatment is completed, individuals may not maintain improvements if they return to distressed social environments that undermine individual coping efforts. thus, it is clear that new interventions derived from integrative models of individual and dyadic coping are needed to alleviate pain and suffering in patients who are at risk for poor treatment outcomes. this research study aims to develop a novel psychological intervention aimed at couples in which one partner has chronic pain. our central hypothesis is that a theoretically integrative intervention that improves both partners' psychological flexibility (i.e., acceptance, mindfulness, values-based action) and relational flexibility (i.e., emotional disclosure, empathic responding) skills will be feasible and valid and that it will alleviate pain and improve quality of life. this is a departure from current practice, which focuses solely on the patient's individual functioning, does not address the spouse's psychological inflexibility, and does not address relationship issues.


Eligibility criteria:
inclusion criteria: * at least one spouse with some pain interference. * relationship dissatisfaction. * both partners at least 21 years old. * couples must also be married or cohabitating for at least 2 years regardless of sexual orientation to participate in the study. exclusion criteria: * current suicidal or homicidal ideation or intent * current psychotic symptoms * cognitive impairment * malignancies (e.g., cancer) in either partner * current domestic violence
study evaluating the etiology of intra-abdominal infections

Conditions: Intra-abdominal Infection

Summary: the aim of this study is to define the etiology of intra-abdominal infections, to study the role of enterococcus spp and pseudomonas aeruginosa in these infections and to clarify the need for specific enterococcal antimicrobial coverage.


Eligibility criteria:
inclusion criteria: * a case will be defined as an intra-abdominal abscess or peritoneal fluid culture that will be positive for enterococcus or an enterococcal bacteriemia in association with an intra-abdominal source of infection. * a control will be defined as a culture-positive intra-abdominal infection or bacteriemia due to an intraabdominal focus where enterococci have not been isolated. exclusion criteria: -

Keywords: abdominal infection
effect of double surgical glove on comfort, sensitivity and dexterity

Conditions: Surgical Gloves

Summary: this clinical trial aims to test the effect of double surgical gloves worn in different sizes on the surgical team's comfort, sensitivity, and dexterity.

the purpose of using surgical gloves is to create a protective barrier against blood-borne pathogens. according to studies, gloves can puncture during surgical procedures. many studies recommend wearing double gloves. however, the world health organization reported that in the guideline for surgical site infections published in 2018, there is not enough evidence for wearing double or single gloves to prevent surgical site infections. however, he recommends that the surgical team prefer to use double gloves to protect themselves against punctures. although wearing double gloves is considered to be positive in terms of patient and employee safety, it is not preferred by the surgical team in some cases. the sense of touch and sensitivity of the human hand is at the center of surgical procedures. finger pulp is extremely sensitive and contains many sensory receptors. placing a barrier, such as a glove, between these sensory receptors and the touched surface may prevent tactile sensitivity in surgical applications. in addition to the advantages of double gloves in terms of patient and employee safety, there are disadvantages such as reduced dexterity and touch sensitivity. in the literature, it has been determined that there are few and old studies examining the effects of double glove use on performance and comfort. therefore, this study, it was aimed to compare the effects of double surgical gloves worn in different procedures or usage habits (double gloves, large and small gloves) on the comfort, sensitivity, and dexterity of the surgical team. the study will conduct as a prospective randomized controlled trial. after obtaining verbal and written consent from the participant, the study will conduct with various data collection forms. these forms are; the introductory information form, surgical glove evaluation form, and visual analogue scale. participants will randomize. after randomization, participants will be included in one of four groups. all procedures will be applied to participants in all groups. group i (n=20), group ii (n=20), group iii (n=20), group iv (n=20). procedure a: double gloves, participants will wear both gloves in their surgical glove size. procedure b: double gloves, participants will wear their own glove number and half a size bigger glove on top. procedure c: double gloves, participants will wear a half-size big glove and their own glove number on top. procedure d: participants will wear one glove (control procedure). open surgeries with a duration of 90-120 minutes will be preferred for evaluation.

Eligibility criteria:
inclusion criteria: taking part in the surgical team six months or more of surgical experience exclusion criteria: latex allergic

Keywords: surgical gloves comfort dexterity sensitivity
study of the kinetics of antibodies against covid-19 (sars-cov-2) and of cellular subpopulations of the immune system

Conditions: COVID-19; Healthy Volunteers; Chronic Disease; Hematological Malignancies; Solid Tumor

Summary: determination of both the degree and duration of the immunity provided after receiving the bnt162b2 vaccine against sars-cov-2.

the purpose of this study is to assess the kinetics of antibodies against sars-cov-2 as well as the kinetics of the immune system's cell subpopulations and cytokines associated with the immune system in healthy volunteers receiving the bnt162b2 vaccine against sars-cov-2 of the pfizer/biontech companies or any other vaccine authorized and administered by the ministry of health. immunoassays will be performed at serum collection points before and after vaccination, as set out in this study.

Eligibility criteria:
inclusion criteria: * healthy volunteers and all individuals who, according to the instructions of the greek state are considered eligible to receive the bnt162b2 vaccine * age ≥ 18 years old exclusion criteria: * serious allergy problems i.e. hospitalization due to a serious allergic reaction (anaphylaxis)

Keywords: covid-19 bnt162b2 vaccine antibodies sars-cov-2
effect of umbilical cord milking versus clamping in preterms on cerebral oxygenation and ductus arteriosus closure

Conditions: Ductus Arteriosus

Summary: all patients will be subjected to the following: 1-umbilical cord milking or delayed cord clamping according to the ranamization table 2 serial measurement of cerebral tissue oxygenation 3- serial echocardiography for ductus arteriosus (da)functional closure

* study population: neonates born and admitted to ain shams university neonatal intensive care units (nicus). * inclusion criteria: o preterm infants with gestational age (ga) of 28 - 34 weeks born and admitted to ain shams university nicus. * exclusion criteria: * late preterm with gestational age 34-37 weeks. * term infants with gestational age \> 37 weeks. * nirs data that was not obtained within 1st hour after birth. * congenital heart disease (other than da or small atrial septal defects/patent foramen oval/ventriculi septal defects). * hypoxic-ischemic insult. * major congenital deformations. #all participants will be subjected to the following: * infants will be considered to be randomized at the time of enrolment for: o delayed cord clamping (dcc) and umbilical cord milking (ucm) * near-infrared spectroscopy (nirs): * in the delivery room: after the intervention (ucm or dcc) the regional cerebral tissue oxygenation (rsco2 ) and cerebral fractional tissue oxygen extraction (c ftoe) will be collected for 10 minutes within 1st hour after birth. * in the neonatal intensive care unit: nirs data will be collected for 2 hours at 12,24 hours, and 48 hours after birth. * echocardiography: will be performed at 6, 12, 18, 24, and 48 hours of life by using an ultrasound doppler machine mindary.m9. assessment of da functioning closure by measuring duct diameter and direction of blood flow through it.

Eligibility criteria:
inclusion criteria: * preterm infants with gestational age (ga) of 28 - 34 weeks born and admitted to ain shams university nicus. exclusion criteria: * late preterm with gestational age 35-37 weeks. * term infants with gestational age \> 37weeks. * nirs data that not obtained within 1sthour after birth. * congenital heart disease (other than pda or small atrial septal defects/patent foramen oval/muscularventriculoseptal defects). * hypoxic-ischemic insult. * major congenital deformations.

Keywords: cerebral tissue oxygenation functional ductus arteriosus closure umbilical cord milking delayed cord clamping
5 year observation of patients with portico valves

Conditions: Aortic Valve Stenosis

Summary: the purpose of this clinical investigation is to further assess the performance and safety profile of the commercially-available portico™ tavi system in patients with severe symptomatic aortic stenosis.

this is an international multicenter, prospective, non-randomized clinical investigation without concurrent or matched control, designed to assess the mid-term safety and performance of the portico valve in patients with severe symptomatic aortic stenosis whom are high risk for surgical valve replacement. the primary endpoint is 1 year all-cause mortality. in addition, the performance and safety profile of the portico valve will be further evaluated at 30 days, 1 year, and annually through 5 years post-implant. the investigation will be conducted at approximately 65 centers in approximately 15 countries in europe, middle-east, africa, canada, australia and new zealand.

Eligibility criteria:
inclusion criteria: * patient has signed the patient informed consent prior to participating in the clinical investigation. * patient has been referred for a portico valve implant as per heart team decision or patient has received a portico valve as per participation in an sjm sponsored regulatory or first-in-human trial. * patient has senile degenerative aortic valve stenosis confirmed by echocardiographically derived criteria\*: * an initial aortic valve area (ava) of less than or equal to (≤) 1.0 cm2 (or indexed eoa less than or equal to (≤) 0.6 cm2/m2) and * a mean gradient greater than (\>)40 mmhg or jet velocity greater than (\>)4.0 m/s or doppler velocity index less than (\ 40 mmhg." (baseline measurement taken by echo within 6 months of index procedure.) * patient has a life expectancy more than (\>) 12 months. for patients enrolled in a french site: * patient is at high risk for surgery as demonstrated by a logistic euroscore equal or more than (≥) 20 and/or a society of thoracic surgeon (sts) mortality risk score of more than (\>) 10% and/or by clinical judgment of the heart team based on the individual risk profile (comorbidities). * not applicable for a patient who has received a portico valve as per participation in an sjm sponsored regulatory or first-in-human trial. exclusion criteria: * any case in which the portico valve would not be indicated for the patient as per current instructions for use (i.e any "off-label" use). * patient has any other aortic valve than tricuspid one. * patient has a prosthetic valve or ring in the aortic position. * patient needs a concomitant structural heart procedure.. * patient needs the usage of an embolic protection device. * patient is unwilling or unable to comply with all clinical investigation-required follow-up evaluations. * patient is pregnant

Keywords: aortic stenosis cv-12-054-eu-pv heart valve prosthesis trans catheter aortic valve replacement tavr trans catheter aortic valve implant tavi
sleep disturbances on postural control in the elderly population

Conditions: Sleep Quality; Postural Stability

Summary: the sleep disorders are common among older adults and comprises of wide spectrum of the sleep related issues like poor sleep quality, sleep deprivation and excessive day time sleepiness.

earlier studies were carried to determine the effect of sleep deprivation on the postural control parameters. the effect of poor sleep quality and excessive daytime sleepiness on the postural control were not widely studied. aim : to determine the effect of the sleep quality and excessive daytime sleepiness on the postural stability during quiet standing and whether this influence vary based on the availability of the visual feedback.

Eligibility criteria:
inclusion criteria: * be able to stand unsupported with eyes opened and eyes closed for 30 seconds. exclusion criteria: * elderly with uncorrected visual impairment, underwent bilateral hip replacement. * participants using drugs which affect control. * participants with previous history of conditions which affect postural control.

Keywords: sleep disturbances postural control elderly population
place of the hevylite test in the evaluation of mrd in myeloma

Conditions: Myeloma

Summary: study aiming at testing the positive predictive value of the hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry

multiple myeloma is a pathology for which treatments are constantly progressing. these treatments allow more and more patients to reach deeper and deeper responses. currently, it is possible to detect very low levels of disease : this is called the evaluation of minimal residual disease. its prognostic value is strong. two techniques currently prevail in the evaluation of minimal residual disease: high throughput sequencing (ngs) and multi-parameter flow cytometry. they are included in evaluation criteria defined by the international myeloma working group (imwg). these techniques have the advantage of being very sensitive, reaching 10-5 (cytometry: 50 events among 5 000 000 cells analysed) to 10-6 (ngs). nevertheless, they are invasive for the patient (medullary specimen), require technical expertise and are not necessarily available in all hospitals. the development of blood tests would cope with this constraints. the hevylite® assay is a simple, sensitive, automated and inexpensive immunologic technique that allows the accurate quantification of total igg, total igg, total iga, total iga l, total igm, and total igm in the blood. given its characteristics, the hevylite assay could play a role in the definition of mrd and allow evaluation of residual disease in myeloma. this study aims to evaluate the positive predictive value of the hevylite test in the evaluation of residual disease in myeloma in comparison with multiparametric flow cytometry on the bone marrow.

Eligibility criteria:
inclusion criteria: -all patients with myeloma in complete response defines as: absence of monoclonal component on serum and urine electrophoresis negative immunofixation on serum and urine normal ratio of free light chains according to the standard freelite® method - any number of treatment lines received exclusion criteria: - no

Keywords: minimal residual disease multi-parametric flow cytometry hevylite®
development of a videogame prototype targeting cigarette and marijuana smoking, and tobacco product prevention among young adolescents (smokescreen)

Conditions: Smoking

Summary: the goal of this sub-study is to learn more about how an educational videogame can feasibly be implemented and disseminated in youth programs.

the specific aims of this sub-study are: specific aim #1: work with game development team to develop a web-based version of smokescreen. specific aim # 2: build a pre-post survey into the smokescreen game to anonymously collect survey information on players' perspectives, beliefs, behaviors around smoking. specific aim # 3: collaborate with youth programs to pilot test the implementation of the new web-based version of smokescreen into youth programs.

Eligibility criteria:
inclusion criteria: * include individuals who have smoked a cigarette previously (since we are evaluating the use of tobacco products in this study, we are including individuals who have previously smoked a cigarette) * willing to sit at a computer/tablet/smartphone and play a video game for 45-60 minutes and answer questions before and after playing the video game. * be enrolled in a youth program that we have a partnership with. exclusion criteria: * does not fit the inclusion criteria.
manual compared to magnetic navigation in ablation for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to compare manual and magnetic navigation in ablation for atrial fibrillation.


Eligibility criteria:
inclusion criteria: * undergoing ablation for atrial fibrillation at st. olavs hospital * implanted reveal

Keywords: atrial fibrillation ablation
prediction model of response for ccrt in esophageal cancer

Conditions: Esophageal Cancer

Summary: 1. retrospective review of old patients * analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 2. prospective case-control study: rna sequencing \& mirna microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy * acquirement of tissue, blood, clinical information * isolation of rna, dna, serum database of clinical \& demographic information \*\*\*analysis of mrna sequencing / mirna sequencing\*\*\*\* first analysis of rna sequencing: bioinformatician second analysis of rna sequencing: principle investigator 3. experimental set for qpcr (esophageal tissue) study group 4. tma for screened exon gene 5. validation set for qpcr (esophageal tissue) 6. follow-up of circulating mirna in blood (baseline blood \& post-ccrt blood 3m, 6m, 12m) 7. prediction model for ccrt response in esophageal cancer based on clinical and molecular factors 8. validate the prediction model.

1. retrospective review of old patients * analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 study group 1. non responder 2. cr but recurrence 3. cr and survival loner than 2 years 2. prospective case-control study: rna sequencing \& mirna microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy --\> acquirement of tissue, blood, clinical information --\> isolation of rna, dna, serum database of clinical \& demographic information study group 1. non-responder (n=14) 2. complete remission (n=14) for considering the drop rate, 2-fold screening \*\*\*analysis of mrna sequencing / mirna sequencing\*\*\*\* first analysis of rna sequencing: bioinformatician second analysis of rna sequencing: principle investigator 3) experimental set for qpcr (esophageal tissue) study group 1. non-responder (n=40) 2. complete remission (n=40) 4) tma for screened exon gene 5) validation set for qpcr (esophageal tissue) new esophageal cancer set 1. non-responder (n=30) 2. complete remission (n=30) 6) follow-up of circulating mirna in blood (baseline blood \& post-ccrt blood 3m, 6m, 12m) 7) prediction model for ccrt response in esophageal cancer based on clinical and molecular factors test several combination models 1. gene + gene combination, 2. gene + clinical information combination, 3. gene + gene + clinical information combination 8) validate the prediction model. 9) primary organoid culture and prediction of chemoradiotherapy response

Eligibility criteria:
inclusion criteria: 1. locally advanced or advanced esophageal cancer who want concomitant chemoradiotherapy 2. persons who assigned the written informed consents. exclusion criteria: 1. persons who did't assign the informed consents 2. other organ cancer 3. heavy alcoholics

Keywords: esophageal cancer chemoradiotherapy response molecular factors
68ga-hsa pet/ct imaging for protein-losing enteropathy

Conditions: Cancer

Summary: in this project, based on the dtpa-has kit, investigators plan to develop a positron nuclide 68ga labeled dtpa-hsa molecular probe in order to obtain high sensitivity, signal-to-noise ratio and high-resolution pet/ct imaging images, aiming to find the specific site of intestinal leakage while diagnosing protein-losing enteropathy (ple), and analyze the pathological mechanism of intestinal leakage in combination with pathology, so as to provide molecular imaging guidance for the treatment of ple patients. ple is a rare gastrointestinal protein-losing syndrome, and the radiopharmaceutical 99mtc-dtpa-hsa (99mtc-human serum albumin) approved by the state food and drug administration has the diagnostic ability of protein-losing enteropathy (ple), but due to the low resolution of spect/ct, the image clarity and signal-to-noise ratio need to be improved, it is a classic probe in the last century, unable to meet the existing clinical needs.

this project developed a a new type of nuclide ga-68 labeled dtpa-hsa probe, and with the inherent advantages of this nuclear medicine department, it has promoted the formulation of the production filing standard of the drug, and obtained the 68ga-hsa injection that can be used for preclinical research and meets the clinical standards. clinical research on 68ga-hsa pet/ct imaging was carried out to provide a basis for the diagnosis and treatment of ple patients.

Eligibility criteria:
inclusion criteria: 1. patients with digestive system tumors; 2. presence of hypoproteinemia or clinical manifestations of hypoplasma protein; 3. serum albumin \ 80 ml/d; 4. measurable lesions in imaging; 5. predicted survival greater than 3 months; exclusion criteria: 1. severe hepatic or renal dysfunction; 2. pregnant or nursing; 3. known allergy to the investigational drug or its excipients in study; 4. unable to comply with the pet/ct imaging procedures; 5. claustrophobia or other psychiatric disorders; 6. other conditions deemed unsuitable for participation in the trial;

Keywords: pet/ct protein-losing enteropathy 68ga labeling human serum albumin